Short Interest in Lonza Group Ag (OTCMKTS:LZAGY) Expands By 79.1%

Lonza Group Ag (OTCMKTS:LZAGYGet Free Report) saw a significant growth in short interest in the month of July. As of July 15th, there was short interest totaling 56,620 shares, a growth of 79.1% from the June 30th total of 31,620 shares. Based on an average daily trading volume, of 88,554 shares, the short-interest ratio is presently 0.6 days. Approximately 0.0% of the company’s stock are short sold.

Lonza Group Stock Performance

Shares of LZAGY stock traded down $1.55 on Friday, hitting $69.59. The stock had a trading volume of 17,804 shares, compared to its average volume of 79,354. The stock’s 50 day moving average is $66.14 and its 200-day moving average is $65.62. Lonza Group has a 52-week low of $58.53 and a 52-week high of $73.85. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.24 and a quick ratio of 1.77.

Analyst Ratings Changes

Separately, Zacks Research upgraded Lonza Group from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 8th. One equities research analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

Get Our Latest Report on LZAGY

About Lonza Group

(Get Free Report)

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.

Featured Stories

Receive News & Ratings for Lonza Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lonza Group and related companies with MarketBeat.com's FREE daily email newsletter.